Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models

Abstract

Antibody antagonists of the insulinotropic receptor GIPR prevent weight gain in obese animal models, and the effect is enhanced by GLP-1R agonists.

Overview

Integrity signals

Registry

Crossref · 10.1126/scitranslmed.aat3392

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 42 references

Cited by

See all 238

Metadata

Authors
Killion, E. A., Wang, J., Yie, J., Shi, S. D.-H., Bates, D., Min, X., Komorowski, R., Hager, T., Deng, L., Atangan, L., Lu, S.-C., Kurzeja, R. J. M., Sivits, G., Lin, J., Chen, Q., Wang, Z., Thibault, S. A., Abbott, C. M., Meng, T., Clavette, B., Murawsky, C. M., Foltz, I. N., Rottman, J. B., Hale, C., Véniant, M. M., & Lloyd, D. J.
Affiliations
  • Amgen (United States) (US)
  • Amgen Research, Department of Cardiometabolic Disorders, Amgen Inc., One Amgen Center Dr., Thousand Oaks, CA 91320, USA.
  • Amgen Research, Department of Therapeutic Discovery, Amgen Inc., One Amgen Center Dr., Thousand Oaks, CA 91320, USA.
  • Amgen Research, Department of Therapeutic Discovery, Amgen Inc., 7990 Enterprise Street, Burnaby, BC V5A 1V7, Canada.
Corresponding author
  • Killion, Elizabeth A.
  • Wang, Jinghong
  • Yie, Junming
  • Lloyd, David J.
Venue
Science Translational Medicine
Published
2018-12-19
Volume
10
Issue
472
ISSN
  • 1946-6234 (ISSN-L)
  • 1946-6242
OpenAlex
W2904833368
Cited by
237
References
42
Citations by year
2026: 32 · 2025: 33 · 2024: 33 · 2023: 28 · 2022: 31 · 2021: 31 · 2020: 20 · 2019: 27
FWCI
11.14
Type
journal article
Language
en
Open access
closed
Locations
  • Science Translational Medicine (publishedVersion)
  • PubMed (publishedVersion)
Funders
Amgen Inc
Topics
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
GIP receptor antagonist, obesity, diet-induced obesity, GLP-1 receptor agonists, combination therapy, weight loss, dietary intake, respiratory exchange ratio, non-human primates, pancreatic beta cells, obesity treatment
MeSH terms
Glucagon-Like Peptide-1 Receptor, Liraglutide, Glucagon-Like Peptide-1 Receptor Agonists, Animals, Antibodies, Diet, Drug Therapy, Combination, Glucagon-Like Peptides, Feeding Behavior, Gastric Inhibitory Polypeptide, Humans, Immunoglobulin Fc Fragments, Mice, Obese, Obesity, Primates, Receptors, Gastrointestinal Hormone, Recombinant Fusion Proteins, Respiration, Weight Gain, Weight Loss, Adipocytes, Insulin-Secreting Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models. https://app.cochat.ai/papers/10.1126/scitranslmed.aat3392
The paper
Killion, E. A., Wang, J., Yie, J., Shi, S. D.-H., Bates, D., Min, X., Komorowski, R., Hager, T., Deng, L., Atangan, L., Lu, S.-C., Kurzeja, R. J. M., Sivits, G., Lin, J., Chen, Q., Wang, Z., Thibault, S. A., Abbott, C. M., Meng, T., . . . Lloyd, D. J. (2018). Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.aat3392

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.